Ardent Health Analysts Revise Forecasts Downward Following Disappointing Q3 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy ARDT?
Source: Benzinga
Earnings Report: Ardent Health Inc reported a loss of 17 cents per share for Q3, missing the analyst estimate of 41 cents, while sales of $1.577 billion exceeded expectations of $1.547 billion.
Guidance Revision: The company lowered its FY2025 GAAP EPS guidance from a range of $1.73-$2.01 to $0.85-$1.03.
Operational Performance: Despite the earnings miss, Ardent Health saw a 5.8% increase in admissions and a 1.4% rise in total surgeries, with revenue and adjusted EBITDA growing by 9% and 46%, respectively.
Analyst Reactions: Following the earnings announcement, Morgan Stanley downgraded the stock from Overweight to Equal-Weight, reducing the price target from $22 to $12, while Stephens & Co. maintained an Overweight rating but lowered the target from $21 to $17.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARDT
Wall Street analysts forecast ARDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDT is 13.73 USD with a low forecast of 10.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 8.580
Low
10.00
Averages
13.73
High
17.00
Current: 8.580
Low
10.00
Averages
13.73
High
17.00
About ARDT
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ardent Health Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Ardent Health and its executives for securities fraud, resulting in a stock price drop of over 33% from $14.05 to $9.30 on November 12, 2025, which undermines investor confidence.
- Financial Misrepresentation: The lawsuit alleges that Ardent Health did not primarily rely on 'detailed reviews of historical collections' for assessing the collectability of accounts receivable, but instead utilized a 180-day cliff, inflating reported receivables and delaying loss recognition, thus violating federal securities laws.
- Revenue Decline: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease due to 'hindsight evaluations of historical collection trends' and increased professional liability reserves by $54 million, leading to a significant stock price drop.
- Investor Action: Investors are encouraged to apply to lead the case by March 9, 2026, with BFA law firm offering legal representation on a contingency fee basis, ensuring shareholders bear no litigation costs.
See More
Ardent Health Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ardent Health and its executives, seeking damages for investors who purchased Ardent securities between July 18, 2024, and November 12, 2025.
- Financial Misrepresentation Claims: The complaint alleges that Ardent Health overstated its third-quarter 2025 revenue due to inadequate assessments of accounts receivable collectability following the transition to a new revenue accounting system, which compromised financial transparency.
- EBITDA Guidance Downgrade: The company's 2025 EBITDA guidance is claimed to be overstated, with a projected reduction of $57.5 million at the midpoint, approximately 9.6%, primarily due to persistent industry-wide cost pressures and payer denials.
- Investor Action Recommendation: Affected investors have until March 9, 2026, to request lead plaintiff status, with the law firm operating on a contingency fee basis, ensuring investors can participate in the lawsuit without upfront costs.
See More
Ardent Health Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Ardent Health in the Middle District of Tennessee on behalf of investors who purchased securities between July 18, 2024, and November 12, 2025, with a deadline of March 9, 2026, to apply as lead plaintiff.
- Financial Issues Exposed: The complaint alleges that Ardent Health reported inflated accounts receivable and delayed recognizing uncollectible losses, resulting in a $43 million revenue drop in Q3 2025, causing the stock price to plummet nearly 34%.
- Insurance Coverage Risks: The company failed to maintain adequate professional malpractice liability insurance to cover potential claims arising from its operations, raising concerns about its future financial stability and investor confidence.
- Investor Rights Advocacy: Bragar Eagel & Squire encourages affected investors to reach out directly to understand their legal rights and potential claims, demonstrating a commitment to protecting investor interests and providing support during this challenging period.
See More
Ardent Health Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Ardent Health and its executives for securities fraud, which has led to a significant stock drop, reflecting serious investor concerns about the company's financial transparency.
- Stock Price Plunge: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease and a $54 million increase in professional liability reserves, causing its stock price to plummet from $14.05 to $9.30, a drop of over 33%, indicating a loss of market confidence in its financial health.
- Financial Transparency Issues: The lawsuit alleges that Ardent Health misrepresented the collectability of its accounts receivable, claiming reliance on “detailed reviews of historical collections,” while actually using a 180-day cliff, which may have misled investors regarding the company's financial condition.
- Legal Implications: Investors have until March 9, 2026, to apply to lead the case, and if the lawsuit succeeds, it could have long-term repercussions on Ardent Health's operations and reputation, further impacting its market performance and investor confidence.
See More
Ardent Health Faces Securities Fraud Class Action
- Lawsuit Deadline: ClaimsFiler reminds Ardent Health investors that lead plaintiff applications must be filed by March 9, 2026, for securities purchased between July 18, 2024, and November 12, 2025, highlighting the legal risks investors face regarding the company's disclosures.
- Significant Revenue Decline: Ardent Health reported a $43 million decrease in Q3 2025 revenue due to a transition to a new revenue accounting system and evaluations of historical collection trends, indicating serious financial management challenges that could undermine investor confidence.
- EBITDA Guidance Cut: The company lowered its 2025 EBITDA guidance to $530 million, down approximately 9.6% from the previous range of $575 million to $625 million, reflecting increasing industry-wide cost pressures that may raise investor concerns about profitability.
- Stock Price Plunge: Following the announcement, Ardent's stock price fell from $14.05 to $9.30 per share, a nearly 34% drop accompanied by unusually high trading volume, signaling a strong market reaction to the company's deteriorating financial health.
See More
Ardent Health Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, to apply as lead plaintiffs by March 9, 2026, to participate in the class action without any out-of-pocket fees.
- False Representation Issues: The lawsuit alleges that Ardent Health made false representations regarding its accounts receivable, failing to accurately reflect their collectability, which resulted in investor losses once the true details were disclosed.
- Insurance Underfunding Risks: Ardent Health did not maintain sufficient professional liability insurance to cover potential claims arising from its operations, particularly facing significant social inflationary pressures in medical malpractice cases in New Mexico.
- Law Firm Expertise: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
See More
Ardent Health Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Ardent Health and its executives for securities fraud, resulting in a stock price drop of over 33% from $14.05 to $9.30 on November 12, 2025, which undermines investor confidence.
- Financial Misrepresentation: The lawsuit alleges that Ardent Health did not primarily rely on 'detailed reviews of historical collections' for assessing the collectability of accounts receivable, but instead utilized a 180-day cliff, inflating reported receivables and delaying loss recognition, thus violating federal securities laws.
- Revenue Decline: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease due to 'hindsight evaluations of historical collection trends' and increased professional liability reserves by $54 million, leading to a significant stock price drop.
- Investor Action: Investors are encouraged to apply to lead the case by March 9, 2026, with BFA law firm offering legal representation on a contingency fee basis, ensuring shareholders bear no litigation costs.
See More
Ardent Health Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ardent Health and its executives, seeking damages for investors who purchased Ardent securities between July 18, 2024, and November 12, 2025.
- Financial Misrepresentation Claims: The complaint alleges that Ardent Health overstated its third-quarter 2025 revenue due to inadequate assessments of accounts receivable collectability following the transition to a new revenue accounting system, which compromised financial transparency.
- EBITDA Guidance Downgrade: The company's 2025 EBITDA guidance is claimed to be overstated, with a projected reduction of $57.5 million at the midpoint, approximately 9.6%, primarily due to persistent industry-wide cost pressures and payer denials.
- Investor Action Recommendation: Affected investors have until March 9, 2026, to request lead plaintiff status, with the law firm operating on a contingency fee basis, ensuring investors can participate in the lawsuit without upfront costs.
See More
Ardent Health Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Ardent Health in the Middle District of Tennessee on behalf of investors who purchased securities between July 18, 2024, and November 12, 2025, with a deadline of March 9, 2026, to apply as lead plaintiff.
- Financial Issues Exposed: The complaint alleges that Ardent Health reported inflated accounts receivable and delayed recognizing uncollectible losses, resulting in a $43 million revenue drop in Q3 2025, causing the stock price to plummet nearly 34%.
- Insurance Coverage Risks: The company failed to maintain adequate professional malpractice liability insurance to cover potential claims arising from its operations, raising concerns about its future financial stability and investor confidence.
- Investor Rights Advocacy: Bragar Eagel & Squire encourages affected investors to reach out directly to understand their legal rights and potential claims, demonstrating a commitment to protecting investor interests and providing support during this challenging period.
See More
Ardent Health Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Ardent Health and its executives for securities fraud, which has led to a significant stock drop, reflecting serious investor concerns about the company's financial transparency.
- Stock Price Plunge: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease and a $54 million increase in professional liability reserves, causing its stock price to plummet from $14.05 to $9.30, a drop of over 33%, indicating a loss of market confidence in its financial health.
- Financial Transparency Issues: The lawsuit alleges that Ardent Health misrepresented the collectability of its accounts receivable, claiming reliance on “detailed reviews of historical collections,” while actually using a 180-day cliff, which may have misled investors regarding the company's financial condition.
- Legal Implications: Investors have until March 9, 2026, to apply to lead the case, and if the lawsuit succeeds, it could have long-term repercussions on Ardent Health's operations and reputation, further impacting its market performance and investor confidence.
See More
Ardent Health Faces Securities Fraud Class Action
- Lawsuit Deadline: ClaimsFiler reminds Ardent Health investors that lead plaintiff applications must be filed by March 9, 2026, for securities purchased between July 18, 2024, and November 12, 2025, highlighting the legal risks investors face regarding the company's disclosures.
- Significant Revenue Decline: Ardent Health reported a $43 million decrease in Q3 2025 revenue due to a transition to a new revenue accounting system and evaluations of historical collection trends, indicating serious financial management challenges that could undermine investor confidence.
- EBITDA Guidance Cut: The company lowered its 2025 EBITDA guidance to $530 million, down approximately 9.6% from the previous range of $575 million to $625 million, reflecting increasing industry-wide cost pressures that may raise investor concerns about profitability.
- Stock Price Plunge: Following the announcement, Ardent's stock price fell from $14.05 to $9.30 per share, a nearly 34% drop accompanied by unusually high trading volume, signaling a strong market reaction to the company's deteriorating financial health.
See More
Ardent Health Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, to apply as lead plaintiffs by March 9, 2026, to participate in the class action without any out-of-pocket fees.
- False Representation Issues: The lawsuit alleges that Ardent Health made false representations regarding its accounts receivable, failing to accurately reflect their collectability, which resulted in investor losses once the true details were disclosed.
- Insurance Underfunding Risks: Ardent Health did not maintain sufficient professional liability insurance to cover potential claims arising from its operations, particularly facing significant social inflationary pressures in medical malpractice cases in New Mexico.
- Law Firm Expertise: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
See More
